In a report released yesterday, Douglas Miehm from RBC Capital reiterated a Hold rating on Novelion Therapeutics Inc (NASDAQ: NVLN), with a price target of $5. The company’s shares closed yesterday at $3.39, close to its 52-week low of $3.08.
Miehm has an average return of 49.1% when recommending Novelion Therapeutics Inc.
According to TipRanks.com, Miehm is ranked #4634 out of 4850 analysts.
Novelion Therapeutics Inc has an analyst consensus of Hold, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.86 and a one-year low of $3.08. Currently, Novelion Therapeutics Inc has an average volume of 77.27K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Novelion Therapeutics, Inc. engages in the development and commercialization of pharmaceuitical products. It focuses in providing new standards of care for individuals living with rare diseases. The company is headquartered in Vancouver, Canada.
